Your browser doesn't support javascript.
loading
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
McGarry, David H; Cooper, Ian R; Walker, Rolf; Warrilow, Catherine E; Pichowicz, Mark; Ratcliffe, Andrew J; Salisbury, Anne-Marie; Savage, Victoria J; Moyo, Emmanuel; Maclean, John; Smith, Andrew; Charrier, Cédric; Stokes, Neil R; Lindsay, David M; Kerr, William J.
Afiliación
  • McGarry DH; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom. Electronic address: d.mcgarry@redxpharma.com.
  • Cooper IR; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom.
  • Walker R; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom.
  • Warrilow CE; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom.
  • Pichowicz M; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom.
  • Ratcliffe AJ; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom.
  • Salisbury AM; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom.
  • Savage VJ; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom.
  • Moyo E; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom.
  • Maclean J; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom.
  • Smith A; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom.
  • Charrier C; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom.
  • Stokes NR; Redx Pharma, Alderley Park, Cheshire SK10 4TG, United Kingdom.
  • Lindsay DM; Department of Pure and Applied Chemistry, University of Strathclyde, WestCHEM, Thomas Graham Building, 295 Cathedral Street, Glasgow G1 1XL, United Kingdom.
  • Kerr WJ; Department of Pure and Applied Chemistry, University of Strathclyde, WestCHEM, Thomas Graham Building, 295 Cathedral Street, Glasgow G1 1XL, United Kingdom.
Bioorg Med Chem Lett ; 28(17): 2998-3003, 2018 09 15.
Article en En | MEDLINE | ID: mdl-30122228
ABSTRACT
According to the World Health Organization (WHO), approximately 1.7 million deaths per year are caused by tuberculosis infections. Furthermore, it has been predicted that, by 2050, antibacterial resistance will be the cause of approximately 10 million deaths annually if the issue is not tackled. As a result, novel approaches to treating broad-spectrum bacterial infections are of vital importance. During the course of our wider efforts to discover unique methods of targeting multidrug-resistant (MDR) pathogens, we identified a novel series of amide-linked pyrimido[4,5-b]indol-8-amine inhibitors of bacterial type II topoisomerases. Compounds from the series were highly potent against gram-positive bacteria and mycobacteria, with excellent potency being retained against a panel of relevant Mycobacterium tuberculosis drug-resistant clinical isolates.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 3_ND Problema de salud: 2_cobertura_universal / 3_tuberculosis Asunto principal: Diseño de Fármacos / Girasa de ADN / Farmacorresistencia Bacteriana Múltiple / Inhibidores de Topoisomerasa II / Bacterias Grampositivas / Antibacterianos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Bioorg Med Chem Lett Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 3_ND Problema de salud: 2_cobertura_universal / 3_tuberculosis Asunto principal: Diseño de Fármacos / Girasa de ADN / Farmacorresistencia Bacteriana Múltiple / Inhibidores de Topoisomerasa II / Bacterias Grampositivas / Antibacterianos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Bioorg Med Chem Lett Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2018 Tipo del documento: Article
...